Global Angina Pectoris Drugs Market Size (2024 - 2029)

The angina pectoris drugs market is anticipated to experience growth due to several factors, including the increasing prevalence of cardiac disorders and the demand for innovative drug delivery systems. The market's expansion is influenced by the rising number of COVID-19 patients with cardiological complications, which has heightened the need for effective angina management. Additionally, advancements in personalized cardiovascular medicine are contributing to market growth. However, challenges such as the adoption of minimally invasive surgeries and potential side effects of certain medications may impede the market's progress.

Market Size of Global Angina Pectoris Drugs Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Surgical Lasers Market Size
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 6.60 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Global Angina Pectoris Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Angina Pectoris Drugs Market Analysis

The Angina Pectoris Drugs Market is expected to register a CAGR of 6.6% during the forecast period, 2022-2027.

COVID-19 severely impacted the angina pectoris market during the early pandemic due to the lockdown restrictions, a decrease in the number of patient hospital visits, and supply chain disruption. For instance, the article titled "COVID-19 Pandemic and Angina Pectoris: What If the Pain Pathway Is Pharmaceutically Modulated?" published in Pain Medicine, in November 2020, stated that the number of cardiovascular patients attending emergency rooms has decreased in the case of COVID-19. Patients have attributed the contradiction to a COVID-19 phobia, meaning that people with angina pectoris avoid going to emergency rooms since they were afraid of becoming infected with the virus. Such incidents negatively impacted the market's growth in the initial phase of the outbreak. However, the demand for angina pectoris drugs is likely to increase with the growing implications of heart disease among COVID-19 patients. For instance, as per a study titled "Long COVID-19 and microvascular disease-related angina" published in Sociedad Española de Cardiología, in November 2021, after meticulous evaluation and exclusion of other illnesses, the researchers found that 27% of the patients evaluated in a long COVID-19 unit had chest pain, some of which was suggestive of angina. A total of 186 patients were enrolled in the trial, 51 (27%) of whom reported ongoing chest pain after being examined in the long COVID-19 unit. Thus, such studies highlighted the need for drugs to manage angina pectoris in COVID-19 patients, ultimately boosting the demand for drugs. Therefore, the growing number of COVID-19 patients with cardiological complications is likely to boost the market's growth over the forecast period.

Furthermore, factors driving the market growth include the rising burden of lifestyle diseases, especially cardiac disorders; technological advancements towards personalized cardiovascular medicine; and the augmentation of novel drug delivery systems.

One of the major driving factors for the market growth is the surge in the patient population suffering from cardiac disorders such as coronary heart disease. For instance, as per the data published by the World Health Organization, in December 2020, ischemic heart disease was the world's leading cause of death, accounting for 16 percent of all deaths. This disease has shown the highest increase in deaths since 2000, increasing by more than 2 million to 8.9 million deaths in 2019. Stroke and chronic obstructive pulmonary disease (COPD) are the second and third largest causes of death, accounting for around 11% and 6% of all deaths, respectively. In addition, an article titled "Angina: contemporary diagnosis and management" published in PubMed Central, in February 2020, stated that Ischemic heart disease (IHD) continues to be the largest cause of death and lost life years in adults, particularly among women under the age of 55. Angina pectoris is a typical clinical manifestation of IHD and is chest discomfort caused by a heart attack. Thus, the growing number of patients suffering from IHD is likely to impel the market growth for angina pectoris drugs over the analysis period, thereby driving the market growth. However, increasing adoption of minimally invasive surgeries and side effects associated with certain drug classes are some of the factors that may hinder the market's growth in the coming years.

Angina Pectoris Drugs Industry Segmentation

As per the scope of the report, Angina pectoris refers to a strangling or pressure-like pain caused by cardiac ischemia. Angina drugs are the initial treatment of angina pectoris. The antianginal drugs recommended for initial treatment are β blockers and calcium channel blockers, which reduce myocardial ischemia by heart rate reduction and vasodilatory mechanisms, respectively. Either or both of these drug classes should be prescribed, together with a short-acting nitrate for prompt alleviation of angina attacks. The Angina Pectoris Drugs Market is segmented by therapeutic class (Beta Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-converting Enzyme Inhibitors, Anti-Platelets, and Others) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (USD million) for all the above segments.

By Therapeutic Class
Beta Blockers
Calcium Channel Blockers
Nitrates
Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
Anti-Platelets
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Angina Pectoris Drugs Market Size Summary

The angina pectoris drugs market is poised for significant growth, driven by an increasing prevalence of cardiac disorders and advancements in cardiovascular medicine. The market experienced initial setbacks due to the COVID-19 pandemic, which led to reduced hospital visits and supply chain disruptions. However, the rising number of COVID-19 patients with cardiological complications has spurred demand for angina pectoris medications. The market is further bolstered by the growing burden of lifestyle diseases, technological innovations in personalized medicine, and the development of novel drug delivery systems. Despite challenges such as the adoption of minimally invasive surgeries and potential side effects of certain drug classes, the market is expected to expand steadily.

North America holds a dominant position in the angina pectoris drugs market, attributed to its robust healthcare infrastructure and the presence of key manufacturers. The high prevalence of ischemic heart disease in the region, coupled with a significant number of clinical trials, fuels market growth. The market is moderately competitive, with major players like Amgen, Bayer AG, and Eli Lilly and Company actively engaging in product development and marketing strategies. Recent regulatory approvals and clinical trials underscore the ongoing efforts to enhance treatment options for angina pectoris, indicating a promising outlook for the market over the forecast period.

Explore More

Global Angina Pectoris Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Burden of Lifestyles Diseases

      2. 1.2.2 Technological Advancements towards Personalized Cardiovascular Medicines

      3. 1.2.3 Augmentation of Novel Drug Delivery Systems

    3. 1.3 Market Restraints

      1. 1.3.1 Increasing Adoption of Minimally Invasive Surgeries

      2. 1.3.2 Side Effects Associated with Certain Drug Classes

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Therapeutic Class

      1. 2.1.1 Beta Blockers

      2. 2.1.2 Calcium Channel Blockers

      3. 2.1.3 Nitrates

      4. 2.1.4 Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)

      5. 2.1.5 Anti-Platelets

      6. 2.1.6 Others

    2. 2.2 Geography

      1. 2.2.1 North America

        1. 2.2.1.1 United States

        2. 2.2.1.2 Canada

        3. 2.2.1.3 Mexico

      2. 2.2.2 Europe

        1. 2.2.2.1 Germany

        2. 2.2.2.2 United Kingdom

        3. 2.2.2.3 France

        4. 2.2.2.4 Italy

        5. 2.2.2.5 Spain

        6. 2.2.2.6 Rest of Europe

      3. 2.2.3 Asia-Pacific

        1. 2.2.3.1 China

        2. 2.2.3.2 Japan

        3. 2.2.3.3 India

        4. 2.2.3.4 Australia

        5. 2.2.3.5 South Korea

        6. 2.2.3.6 Rest of Asia-Pacific

      4. 2.2.4 Middle East and Africa

        1. 2.2.4.1 GCC

        2. 2.2.4.2 South Africa

        3. 2.2.4.3 Rest of Middle East and Africa

      5. 2.2.5 South America

        1. 2.2.5.1 Brazil

        2. 2.2.5.2 Argentina

        3. 2.2.5.3 Rest of South America

Global Angina Pectoris Drugs Market Size FAQs

The Global Angina Pectoris Drugs Market is projected to register a CAGR of 6.60% during the forecast period (2024-2029)

Amgen, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline Plc. and Bayer AG are the major companies operating in the Global Angina Pectoris Drugs Market.

Angina Pectoris Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)